Therapies

6–9 minutes

read

Tavapadon vs. Solengepras: Two New Parkinson’s Treatments Compared

For more than 50 years, levodopa has been the backbone of Parkinson’s treatment. Over time, many people notice their medication wearing off between doses, which brings back stiffness, slowness or tremor. Doctors call these periods “OFF time.” Two new once-daily pills aim to help, and they take very different routes.

Our earlier article covers tavapadon in more depth: The most important advances in PD research 2026, part 2: tavapadon for Parkinson’s disease.

Where do they stand?

Tavapadon (brand name Juvmo) is approved. The FDA approved it for adults with Parkinson’s disease, and the manufacturer AbbVie announced the approval on September 28, 2026. It is expected to be available in the US in October 2026. The approval covers people in early disease as well as those taking levodopa who have OFF periods.

Solengepras is not approved. It has completed a Phase 3 trial called ARISE, and its developer, Cerevance, announced the results on October 7, 2026. The company plans to meet with the FDA to discuss next steps. No application has been filed yet, and approval is not guaranteed.

How do they work?

Tavapadon works with dopamine. It is a “D1/D5 agonist,” which means it switches on certain dopamine receptors in the brain’s movement circuit. It switches them on only partway (“partial agonist”). Older dopamine-like drugs mostly activate a different family of receptors (D2/D3).

Solengepras does not touch dopamine at all. It targets GPR6, a receptor found on nerve cells in the brain’s “indirect pathway,” a circuit that acts as a brake on movement. GPR6 is normally slightly active all the time, and solengepras turns that background activity down. The aim is to rebalance the movement circuits without changing dopamine signaling directly. It would be a completely new class of medicine. In laboratory studies, it reached the brain after being taken by mouth and restored movement in animal models of Parkinson’s, and GPR6 was found in the brain tissue of people with Parkinson’s. That is early evidence, which is why the human trials matter.

Why aim at one target?

Most dopamine agonists on the market, drugs that mimic dopamine, act mainly on D2/D3 receptors. They can help, but they are also linked to sleepiness, hallucinations, swelling, low blood pressure on standing, and impulse-control problems such as compulsive gambling or shopping. In some studies, up to about 1 in 6 people taking them developed impulse-control problems.

Both new drugs try to avoid this by being more targeted. Tavapadon barely acts on D3, the receptor linked to those problems, and its partial action is also meant to lower the risk of dyskinesia (involuntary movements). Solengepras skips dopamine receptors altogether.

But so far, this is a promise, not proof. No trial has compared either drug directly with an older dopamine agonist, and none has run longer than 27 weeks. For tavapadon, the trials showed no clear excess of impulse-control problems compared with placebo, but there were very few cases. Independent reviewers rate this evidence as very low certainty and cannot rule out a risk. The label also warns that unusual urges can occur. For solengepras, no data on impulse-control problems are available yet.

How well do they work?

The key measure is how many more hours per day a person feels well. The two studies are not directly comparable, because they differed in length, size and design.

  • Tavapadon (TEMPO-3, 507 people, 27 weeks, published in JAMA Neurology): Compared with placebo, people gained about 1.1 more hours of “good ON time” (movement without troublesome dyskinesia), and OFF time fell by about 0.9 more hours. A 2026 review in Neurological Sciences pooled the add-on trials and found almost the same gain (1.09 hours per day). It rated the motor benefit as moderate certainty, which was the highest certainty any outcome in that review received.
  • Solengepras 150 mg (ARISE, 341 people, 12 weeks, reported by the company): Compared with placebo, OFF time fell by about 0.6 more hours, and ON time without troublesome dyskinesia rose by about 0.6 hours. Benefit appeared as early as week 2. Everyday function, daytime sleepiness and quality of life also improved.

Everyone in both trials kept taking their usual Parkinson’s medication.

What about side effects?

Tavapadon. More people on tavapadon reported side effects than on placebo (71.7% vs 55.1% in TEMPO-3), but 93.2% of these were not serious, and most were mild to moderate. The most common were nausea (14.3%), dyskinesia (10.0%) and dizziness (7.6%). Nausea mostly appears while the dose is being increased and tends to ease with time. Blood pressure drops slightly, but the trials did not show more fainting. The pooled review found that serious side effects were not increased, but more people on tavapadon stopped treatment because of side effects. Anyone taking it should tell their doctor or family about any new compulsive behavior.

Solengepras. In ARISE, 3.5% of people stopped treatment because of side effects, the same as on placebo. No serious side effects were reported at the 150 mg dose. Dyskinesia occurred in 4.4% (vs 1.8% on placebo). The most common side effects were headache (8.0%) and urinary tract infections (8.0%), followed by insomnia (6.2%) and nausea (6.2%). The trial found fewer typical dopamine-type side effects. Because ARISE was shorter than the tavapadon trials and no head-to-head data exist, the numbers can’t be compared directly, and longer-term safety is still unknown.

At a glance

CategoryTavapadonSolengepras
StatusFDA-approvedPhase 3 complete; FDA talks planned
How it worksSwitches on D1/D5 dopamine receptorsTurns down GPR6, no direct dopamine action
Extra ON time vs placebo~1.1 h (good ON time)~0.6 h (ON without troublesome dyskinesia)
Less OFF time vs placebo~0.9 h~0.6 h
Trial length27 weeks12 weeks
Stopped due to side effectsMore often than placebo (pooled review)3.5%, same as placebo
Common side effectsNausea, dyskinesia, dizzinessHeadache, UTI, insomnia, nausea
Source of evidencePeer-reviewed trials and reviewsCompany announcement, conference abstract

How strong is the evidence?

For tavapadon, independent reviewers rated the motor benefit as moderate certainty and found no outcome with high certainty. For solengepras, the evidence so far is one Phase 3 trial reported by the company, plus an earlier Phase 2 study and laboratory work. Both treatments need longer-term data and head-to-head comparisons.

What does this mean for you?

Tavapadon is the option that exists today, with larger and longer trial data, but with more side effects than placebo. Solengepras looks gentler so far and offers a brand-new mechanism, but its results are shorter, smaller in effect and not yet peer-reviewed. Neither is a cure, and neither has been shown to be safer than older dopamine agonists.

If you want to know whether either option might suit you, talk to your neurologist. Don’t change your medication on your own.

Important notice — not medical advice

This article is an informational overview from Kill Parkinson gUG (KiPa). It does not replace medical diagnosis, treatment recommendations or advice. Decisions about Parkinson’s therapy — in particular a switch or an addition to levodopa preparations — belong exclusively in the hands of your treating neurologist.

All information provided to the best of our knowledge, with reference to the original sources cited in the text. Our team uses AI to work faster, but every article is reviewed by a human expert.

Sources

  1. Fernandez HH, Isaacson SH, Hauser RA, et al. Tavapadon as adjunctive treatment for Parkinson disease: the TEMPO-3 randomized clinical trial. JAMA Neurol. 2026;83(5):442-451. doi:10.1001/jamaneurol.2026.0577
  2. Rashid AA, Mohammad A, Malik U, et al. Efficacy, safety and certainty of evidence for selective D1/D5 dopamine receptor partial agonists in Parkinson’s disease: a systematic review, meta-analysis and GRADE assessment. Neurol Sci. 2026;47:708. doi:10.1007/s10072-026-09306-8
  3. Alsharif M, Shrebaty O, Aloudah MA, et al. Tavapadon in Parkinson’s disease: D1/D5 receptor pharmacology, clinical evidence, and translational perspectives (narrative review). Front Aging Neurosci. 2026. doi:10.3389/fnagi.2026.1959744
  4. Cerevance. Positive Phase 3 ARISE results for solengepras (press release), October 7, 2026. Company-reported, not peer-reviewed.
  5. Chou K, Brice N, Scholl C, et al. Solengepras (CVN424): a novel GPR6 inhibitor in clinical development as an investigational therapy for Parkinson’s disease (P11-5.017). Neurology. 2025;104(7 Suppl 1):2892. Conference abstract, not reviewed by the journal. doi:10.1212/WNL.0000000000210649
  6. Brice NL, Schiffer HH, Monenschein H, Mulligan VJ, Page K, Powell J, Xu X, Cheung T, Burley JR, Sun H, Dickson L. Development of CVN424: a selective and novel GPR6 inverse agonist effective in models of Parkinson disease. The Journal of Pharmacology and Experimental Therapeutics. 2021 Jun 1;377(3):407-16.  doi:10.1124/jpet.120.000438
  7. Weintraub D, Koester J, Potenza MN, Siderowf AD, Stacy M, Voon V, Whetteckey J, Wunderlich GR, Lang AE. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Archives of neurology. 2010 May 1;67(5):589-95. doi:10.1001/archneurol.2010.65
  8. AbbVie. FDA approves JUVMO (tavapadon) for Parkinson’s disease (press release), September 28, 2026.